PROPEL: a randomized, phase Ill trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Clarke, Noel W Armstrong, AJ Thiery-Vuillemin, A Oya, M Ye, DW Mateo, J Goessl, CD Kang, JY Liu, S Saad, F
Clarke, Noel W
Armstrong, AJ
Thiery-Vuillemin, A
Oya, M
Ye, DW
Mateo, J
Goessl, CD
Kang, JY
Liu, S
Saad, F
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Ye D, Mateo J, et al. PROPEL: a randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2019;37(7_suppl):TPS340-TPS.